β-Τhalassaemia
-
News
JUST RELEASED | 5th Edition of TIF’s Guidelines for the Management of Transfusion Dependent β-Thalassaemia
This edition stands as a seminal resource that provides critical guidance and recommendations to healthcare professionals across various specialties, researchers and all stakeholders involved in the care of individuals affected…
Read More » -
News
CASGEVY | 1st Gene-Editing Therapy for Thalassaemia and SCD Approved in UK
Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. The therapy, developed by…
Read More » -
News
TOP STORY | EMA Validates Vertex’s/CRISPR Submission Of Exa-Cel For β-Τhal And SCD
The Marketing Authorization Application (MAA) for exagamglogene autotemcel (exa-cel), marks the first regulatory submission in the EU for a CRISPR-based medicine. Through the validation, exa-cel is indicated for the…
Read More »